Sign Up Now to Download a Free Research Report on IMGN

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts





Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

ImmunoGen, Inc

ImmunoGen shares declined 16 percent after reporting losses widened to $25.2 million in the fiscal first quarter, from to a net loss of $19.5 million in the year-ago quarter. The company expects to file for marketing approval of its cancer drug T-DM1 in 2015.

Going forward ... (see research report)



RESEARCH REPORT ON IMGN Download Free Report Now


Preview Pages of Actual Equity Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on